Efficacy and tolerability of Sativex® in MS spasticity

A cannabis derived drug which has been approved in some countries to treat muscle spasticity.

Efficacy and tolerability of Sativex® in MS spasticity

Postby MSUK » Mon Oct 24, 2011 3:48 am


Almirall, S.A. presented full results from three Phase III studies with Sativex®, in a satellite symposium at the 27th ECTRIMS congress,which took place in Amsterdam from 19th to 22nd October 2011.

These Phase III studies provide evidence of the long term efficacy of Sativex® (2.7 mg delta-9-tetrahydrocannabinol and 2.5 mg cannabidiol per puff) in symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814
MS-UK - http://www.ms-uk.org/
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Return to Sativex


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service